Literature DB >> 2161588

Drugs of abuse--opiates.

W Ling1, D R Wesson.   

Abstract

Treating opiate-dependent patients can be difficult for many physicians because the patients' life-styles, values, and beliefs differ from those of the physicians. Primary care physicians, however, are often involved in the treatment of the medical complications of opiate abuse, and physicians must often manage a patient's opiate dependence until appropriate referral to a drug abuse treatment program can be arranged. Treatment is guided by an understanding of the patient's addictive disease, for which there are specific diagnostic criteria, and an understanding of the pharmacology of opiates of abuse and the medications used in treating opiate dependence. The opiate agonist, methadone, is useful for both detoxification and maintenance. The opiate antagonist, naloxone, is the treatment of choice for opiate overdose, and naltrexone, also an opiate antagonist, is a useful adjunct in subgroups of opiate-dependent patients for preventing relapse. New medications for the treatment of opiate dependence are being developed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161588      PMCID: PMC1002412     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  14 in total

1.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

2.  Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

Authors:  W R Martin; D R Jasinski; P A Mansky
Journal:  Arch Gen Psychiatry       Date:  1973-06

3.  Clonidine for outpatient opiate detoxification.

Authors:  A M Washton; R B Resnick; R A Rawson
Journal:  Lancet       Date:  1980-05-17       Impact factor: 79.321

4.  Women on LAAM maintenance: initial experiences.

Authors:  W A Hargreaves; W Ling; T C Brown; J A Weinberg; R Landsberg; W L Harrison
Journal:  J Psychedelic Drugs       Date:  1979 Jul-Sep

5.  Buprenorphine effects on human heroin self-administration: an operant analysis.

Authors:  N K Mello; J H Mendelson; J C Kuehnle
Journal:  J Pharmacol Exp Ther       Date:  1982-10       Impact factor: 4.030

6.  A case of buprenorphine abuse.

Authors:  A J Quigley; D E Bredemeyer; S S Seow
Journal:  Med J Aust       Date:  1984-03-31       Impact factor: 7.738

7.  Buprenorphine detoxification from opioid dependence: a pilot study.

Authors:  T R Kosten; H D Kleber
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

8.  A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

9.  Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment.

Authors:  M S Gold; A C Pottash; D R Sweeney; H D Kleber
Journal:  JAMA       Date:  1980-01-25       Impact factor: 56.272

10.  Buprenorphine suppresses cocaine self-administration by rhesus monkeys.

Authors:  N K Mello; J H Mendelson; M P Bree; S E Lukas
Journal:  Science       Date:  1989-08-25       Impact factor: 47.728

View more
  6 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

Review 2.  Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives.

Authors:  L Stavitskaya; A Coop
Journal:  Mini Rev Med Chem       Date:  2011-10       Impact factor: 3.862

3.  Effects of sleep deprivation on sleep homeostasis and restoration during methadone-maintenance: a [31]P MRS brain imaging study.

Authors:  George H Trksak; J Eric Jensen; David T Plante; David M Penetar; Wendy L Tartarini; Melissa A Maywalt; Michael Brendel; Cynthia M Dorsey; Perry F Renshaw; Scott E Lukas
Journal:  Drug Alcohol Depend       Date:  2009-09-22       Impact factor: 4.492

4.  The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.

Authors:  Sunil Sirohi; Shveta V Dighe; Priyanka A Madia; Byron C Yoburn
Journal:  J Pharmacol Exp Ther       Date:  2009-05-12       Impact factor: 4.030

5.  Substance abuse and AIDS: a faculty development program for primary care providers.

Authors:  P G O'Connor; J Bigby; D Gallagher
Journal:  J Gen Intern Med       Date:  1993-05       Impact factor: 5.128

6.  Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project.

Authors:  William R Lovallo; Andrea C King; Noha H Farag; Kristen H Sorocco; Andrew J Cohoon; Andrea S Vincent
Journal:  Psychoneuroendocrinology       Date:  2012-05-08       Impact factor: 4.905

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.